XORTX Therapeutics Inc. (XRTX.V)

CAD 1.62

(-7.43%)

Total Debt Summary of XORTX Therapeutics Inc.

XORTX Therapeutics Inc.'s latest annual total debt in 2023 was 15.17 Thousand CAD , down -80.4% from previous year.
XORTX Therapeutics Inc.'s latest quarterly total debt in 2024 Q2 was 83.7 Thousand USD , up 496.32% from previous quarter.
XORTX Therapeutics Inc. reported annual total debt of 77.44 Thousand CAD in 2022, down 0.0% from previous year.
XORTX Therapeutics Inc. reported annual total debt of - CAD in 2021, down 0.0% from previous year.
XORTX Therapeutics Inc. reported quarterly total debt of 83.7 Thousand USD for 2024 Q2, up 496.32% from previous quarter.
XORTX Therapeutics Inc. reported quarterly total debt of 11.51 Thousand USD for 2023 Q4, down -59.63% from previous quarter.

Annual Total Debt Chart of XORTX Therapeutics Inc. (2023 - 2014)

Historical Annual Total Debt of XORTX Therapeutics Inc. (2023 - 2014)

Year	Total Debt	Total Debt Growth
2023	15.17 Thousand CAD	-80.4%
2022	77.44 Thousand CAD	0.0%
2021	- CAD	0.0%
2020	- CAD	-100.0%
2019	50.81 Thousand CAD	17.47%
2018	43.25 Thousand CAD	-84.12%
2017	272.46 Thousand CAD	119.5%
2016	124.12 Thousand CAD	0.0%
2014	- CAD	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	14.03 Thousand USD	21.95%
2024 Q2	83.7 Thousand USD	496.32%
2023 Q4	11.51 Thousand USD	-59.63%
2023 FY	15.17 Thousand CAD	-80.4%
2023 Q1	61.53 Thousand USD	-41.45%
2023 Q2	45.18 Thousand USD	-26.57%
2023 Q3	28.51 Thousand USD	-36.9%
2022 Q1	- CAD	0.0%
2022 Q4	105.1 Thousand CAD	-16.87%
2022 FY	77.44 Thousand CAD	0.0%
2022 Q3	126.43 Thousand CAD	-14.18%
2022 Q2	147.33 Thousand CAD	0.0%
2021 Q4	- CAD	0.0%
2021 Q3	- CAD	0.0%
2021 Q2	- CAD	0.0%
2021 FY	- CAD	0.0%
2021 Q1	- CAD	0.0%
2020 FY	- CAD	-100.0%
2020 Q2	- CAD	-100.0%
2020 Q1	52.82 Thousand CAD	3.96%
2020 Q4	- CAD	0.0%
2020 Q3	- CAD	0.0%
2019 Q2	47 Thousand CAD	4.15%
2019 FY	50.81 Thousand CAD	17.47%
2019 Q1	45.13 Thousand CAD	4.35%
2019 Q4	50.81 Thousand CAD	3.89%
2019 Q3	48.9 Thousand CAD	4.04%
2018 Q4	43.25 Thousand CAD	4.72%
2018 Q2	39.94 Thousand CAD	5.1%
2018 Q3	41.3 Thousand CAD	3.42%
2018 Q1	38 Thousand CAD	-86.05%
2018 FY	43.25 Thousand CAD	-84.12%
2017 Q2	- CAD	0.0%
2017 Q4	272.46 Thousand CAD	18.9%
2017 FY	272.46 Thousand CAD	119.5%
2017 Q1	- CAD	0.0%
2017 Q3	229.15 Thousand CAD	0.0%
2016 Q4	- CAD	0.0%
2016 Q3	- CAD	0.0%
2016 Q2	- CAD	0.0%
2016 Q1	- CAD	0.0%
2016 FY	124.12 Thousand CAD	0.0%
2015 Q4	- CAD	0.0%
2015 Q3	- CAD	0.0%
2015 Q2	- CAD	0.0%
2015 Q1	- CAD	0.0%
2014 FY	- CAD	0.0%

Peer Total Debt Comparison of XORTX Therapeutics Inc.

Name	Total Debt	Total Debt Difference
Arch Biopartners Inc.	5.01 Million CAD	99.697%
Covalon Technologies Ltd.	1.56 Million CAD	99.029%
Hemostemix Inc.	4.32 Million CAD	99.649%
Universal Ibogaine Inc.	1.73 Million CAD	99.127%
Kane Biotech Inc.	8.27 Million CAD	99.817%
MedMira Inc.	9.27 Million CAD	99.836%
Marvel Biosciences Corp.	1 Million CAD	98.482%
NervGen Pharma Corp.	197.19 Thousand CAD	92.303%